Premium
Lexicon Pharmaceuticals Inc (LXRX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Dr. Judith Lea SwainIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 174,49k | 104,86% |
| 2026-06-03 | Ms. Diane E. SullivanIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 126,12k | 242,63% |
| 2026-06-03 | Mr. Christopher J. SobeckiIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 293,18k | 43,81% |
| 2026-06-03 | Mr. Ivan H. CheungIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 89,31k | - |
| 2026-06-03 | Dr. Samuel L. BarkerIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 213,77k | 71,76% |
| 2026-06-03 | Mr. Philippe J. AmouyalIndependent Director | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 374,49k | 31,32% |
| 2026-06-03 | Mr. Raymond DebbaneIndependent Chairman of the Board | 89,31k | 0,00 | Derivative Exercise and Retained Stock | - | 2,00M | 4,69% |
| 2026-04-30 | Artal Group S.A.Société | 20,42M | 0,00 | Derivative Exercise and Retained Stock | - | 175,16M | 13,20% |
| 2026-02-28 | Ms. Wendy E. McDermottSVP of HR | 156,30k | 0,00 | Derivative Exercise and Retained Stock | - | 277,95k | 128,49% |
| 2026-02-28 | Ms. Wendy E. McDermottSVP of HR | -68,11k | 100,12k | Derivative Exercise and Sale | 1,47 | 277,95k | - |
| 2026-02-28 | Ms. Rachel Yap MartensSenior VP of Partnerships & Corporate Strategy | 31,26k | 0,00 | Derivative Exercise and Retained Stock | - | 31,26k | - |
| 2026-02-28 | Ms. Rachel Yap MartensSenior VP of Partnerships & Corporate Strategy | -35,83k | 52,66k | Derivative Exercise and Sale | 1,47 | 31,26k | - |
| 2026-02-28 | Dr. Craig B. GranowitzSenior VP & Chief Medical Officer | 203,18k | 0,00 | Derivative Exercise and Retained Stock | - | 323,43k | 168,96% |
| 2026-02-28 | Dr. Craig B. GranowitzSenior VP & Chief Medical Officer | -109,10k | 160,37k | Derivative Exercise and Sale | 1,47 | 323,43k | - |
| 2026-02-28 | Dr. Suma GopinathanSVP of Discovery | 75,61k | 0,00 | Derivative Exercise and Retained Stock | - | 150,13k | 101,47% |
| 2026-02-28 | Dr. Suma GopinathanSVP of Discovery | -24,34k | 35,78k | Derivative Exercise and Sale | 1,47 | 150,13k | - |
| 2026-02-28 | Ms. Lisa M. DeFrancescoSVP of Investor Relations & Corporate Communications | 78,29k | 0,00 | Derivative Exercise and Retained Stock | - | 93,87k | 502,61% |
| 2026-02-28 | Ms. Lisa M. DeFrancescoSVP of Investor Relations & Corporate Communications | -74,57k | 109,62k | Derivative Exercise and Sale | 1,47 | 93,87k | - |
| 2026-02-28 | Mr. Scott M. CoianteSenior VP & CFO | 105,36k | 0,00 | Derivative Exercise and Retained Stock | - | 105,36k | - |
| 2026-02-28 | Mr. Scott M. CoianteSenior VP & CFO | -54,88k | 80,68k | Derivative Exercise and Sale | 1,47 | 105,36k | - |
| 2026-02-28 | Mr. Brian T. CrumSenior VP, General Counsel & Secretary | 167,99k | 0,00 | Derivative Exercise and Retained Stock | - | 428,80k | 64,41% |
| 2026-02-28 | Mr. Brian T. CrumSenior VP, General Counsel & Secretary | -105,02k | 154,38k | Derivative Exercise and Sale | 1,47 | 428,80k | - |
| 2026-02-28 | Dr. Michael S. ExtonCEO & Director | 298,43k | 0,00 | Derivative Exercise and Retained Stock | - | 298,43k | - |
| 2026-02-28 | Dr. Michael S. ExtonCEO & Director | -204,83k | 301,10k | Derivative Exercise and Sale | 1,47 | 298,43k | - |
| 2026-02-25 | Mr. Raymond DebbaneIndependent Chairman of the Board | 2,00k | 2,98k | Achat | 1,49 | 1,91M | 0,11% |
| 2026-02-23 | Mr. Raymond DebbaneIndependent Chairman of the Board | 100,00k | 147,00k | Achat | 1,47 | 1,90M | 5,54% |
| 2026-02-19 | Mr. Raymond DebbaneIndependent Chairman of the Board | 150,00k | 219,76k | Achat | 1,44 - 1,48 | 1,80M | 9,07% |
| 2026-02-13 | Mr. Raymond DebbaneIndependent Chairman of the Board | 268,50k | 352,89k | Achat | 1,31 - 1,32 | 1,65M | 19,38% |
| 2026-02-02 | Artal Group S.A.Société | 1,54M | 2,00M | Achat | 1,30 | 199,04M | 0,78% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
